Navigation Links
Study of tenofovir vaginal gel shows daily dosing ineffective due to lack of adherence
Date:3/4/2013

ARLINGTON, VIRGINIA (12:15 EST MARCH 4, 2013) Researchers with the Microbicide Trials Network (MTN) today announced results of the Vaginal and Oral Interventions to Control the Epidemic (VOICE) study at the Conference for Retroviruses and Opportunistic Infections (CROI) in Atlanta, Georgia. The VOICE study tested oral and vaginal antiretroviral-based approaches as HIV prevention methods in 5,029 women in South Africa, Uganda, and Zimbabwe. Funded by the U.S. National Institutes of Health and managed by the MTN, the VOICE study was a major undertaking, which has provided important data regarding drug safety, effectiveness, acceptability and adherence.

"The principal investigators of the study, Drs. Jeanne Marazzo and Zvavahera Mike Chirenje, and the entire VOICE team have done an outstanding job," said CONRAD Executive Director Gustavo Doncel, M.D., Ph.D.

VOICE launched in September 2009 as a Phase IIB safety and effectiveness study to compare 3 different once-daily HIV prevention strategies: 1) a pill of combination emtricitabine and tenofovir (Truvada), 2) a pill containing only tenofovir (Viread), and 3) tenofovir 1% vaginal gel. Study participants received ongoing HIV risk-reduction counseling, condoms, and diagnosis and treatment of sexually transmitted infections throughout the trial. They were tested monthly for HIV and quarterly for drug levels.

In an evaluation of plasma samples in a subset of the women, drug was detected on average in 28% of participants taking oral tenofovir, 29% of participants taking oral Truvada, and 23% of participants in the vaginal gel study arm. Unfortunately, due to the low adherence, none of the products were deemed effective in reducing HIV acquisition in this particular trial. The estimates of effectiveness for both oral tenofovir and Truvada were less than zero. The study showed a 14.7% reduction of HIV infection in the tenofovir gel arm, when compared to placebo gel. This level of protection, however, was not statistically significant.

Some of the previous studies using the same antiretrovirals in tablet or gel form for HIV prevention showed effectiveness. In particular, CAPRISA 004, a study completed in 2010 using the same tenofovir vaginal gel used in the VOICE trial, showed an average of a 39% reduction in HIV infections and a 54% reduction in women who used it at least 80% of the time. Additionally, tenofovir gel reduced the risk of herpes genital infections by 51%. The dosing regimen was different than the daily dosing used in the VOICE study women in CAPRISA 004 were required to insert 1 dose before sex and 1 dose after sex, not to exceed 2 doses in 24 hours (a regimen dubbed BAT24). CAPRISA 004 was the first trial to show that a topical product containing tenofovir could reduce HIV infection and suggests that a dosing method that requires women to use the product around the time of sex, versus daily dosing, may be preferable to women.

To that end, FACTS 001, a study sponsored by CONRAD, funded by USAID, the Bill & Melinda Gates Foundation and the South African government, and co-chaired by the South African scientists, Drs. Helen Rees and Glenda Gray, is currently being conducted at 9 sites in South Africa. The trial replicates the dosing regimen used in CAPRISA 004 (i.e., BAT 24). FACTS 001 is using a variety of methods to collect information about gel use, condom use, and sexual behavior in order to measure adherence. The study has enrolled close to 1,900 participants and is expected to be complete at the end of 2014. FACTS 001 is an important study as it is designed to confirm the results obtained in CAPRISA 004 and contribute to the approval of tenofovir gel as a pericoital method for prevention of HIV infection in women.

The VOICE study also found that single women under 25 were the least likely to use the product and the most likely to acquire HIV. "The VOICE results highlight the gravity of the epidemic, especially in young, unmarried women, and the importance of developing products that appeal to them. At CONRAD, we remain committed to designing HIV prevention products based on innovation and sound product development strategies," said Dr. Doncel.

"The results of the CAPRISA 004 and VOICE trials illustrate that there are some women who may only want to use a product when they know they are having sex and the FACTS 001 study plays a very important role in testing that hypothesis. We need more information on the type of products that women who are at the highest risk level want and will use," said Dr. Jill Schwartz, CONRAD's Medical Director.


'/>"/>

Contact: Annette Larkin
alarkin@conrad.org
703-772-6427
CONRAD
Source:Eurekalert

Related medicine news :

1. Study Suggests Vaccine May Help Kids With Brain Cancer
2. Study reveals how cancer drug causes diabetic-like state
3. Coffee Drinking in Pregnancy Wont Lead to Sleepless Baby: Study
4. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
5. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
6. No Added Cancer Risk From Hip Replacement Materials: Study
7. Reported Decline in U.S. Pneumonia Deaths May Be False: Study
8. Early Study Finds Some Promise for Lung Cancer Vaccine
9. Narcissists Often Ace Job Interviews, Study Finds
10. Sexual objectification of female artists in music videos exists regardless of race, MU study finds
11. Soy may alleviate hot flashes in menopause, large-scale study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... , ... February 22, 2017 , ... Super-Sod will attend ... 26 event in Athens, Georgia. , A shift from Super-Sod’s simple Athens Home Show ... , For the booth, grass seed plant manager Chris Roquemore constructed furniture from recycled ...
(Date:2/22/2017)... ... 2017 , ... Pet obesity in the U.S. continued to steadily increase in ... for Pet Obesity Prevention (APOP). During the ninth annual survey, APOP also found pet ... of corn and grains, value of raw and organic diets, and the best sources ...
(Date:2/22/2017)... ... February 22, 2017 , ... Social media marketing is transitioning from a singular ... Smith & Jones’ delves into this insight and more in its latest episode of ... David Vener meets up with social media strategist and partner of the digital firm ...
(Date:2/22/2017)... ... February 22, 2017 , ... FPS ... from combat-related PTSD. , Established in 1977, our organization was at the forefront ... military returning to civilian life were evident and served as the catalyst for ...
(Date:2/22/2017)... ... February 22, 2017 , ... BrightStar Care Charleston , a home ... University of South Carolina (MUSC) Center on Aging’s Senior Expo on Thursday, March ... Aging is a tremendous resource in our community. We are thrilled to participate in ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... , Colombie-Britannique, February 22, 2017 Des scanners sur ... vente en Europe , au Moyen-Orient et en Afrique  ... Clarius Mobile Health , ... Vancouver , au Canada , a annoncé ... des Scanners Échographiques Sans fil Clarius C3 et L7, destinés à être ...
(Date:2/22/2017)... Nordic Nanovector ASA (OSE: NANO), a biopharmaceutical company focusing ... cancers, will announce its fourth quarter and full year 2016 results ... ... will take place at 8:30 am CET at: Thon ... The presentation will be recorded as a webcast and will ...
(Date:2/22/2017)... February 22, 2017 Indivumed, GmbH (Indivumed), a ... and The Indian Institute of Technology Madras (IITM), the ... the first Indian national cancer data base and biobank for use ... ... term. The collaboration will include collection of many types of cancer, ...
Breaking Medicine Technology: